EC Number   |
Application |
Reference |
|---|
   3.4.22.65 | diagnostics |
maturation systems using Pro-Der p 1 without the prodomain glycosylation are useful for the efficient preparation of a recombinant mature allergen |
665201 |
| 3.4.22.65 | diagnostics |
possible development of diagnostic allergy tests based on in planta produced allergens using Der 1 p as prototype |
732955 |
| 3.4.22.65 | diagnostics |
production of recombinant enzymatically and immunologically enzyme for diagnostic testing |
732865 |
| 3.4.22.65 | diagnostics |
suspension-cultured BY-2 tobacco cells represent a low cost and environmentally safe expression system suitable to produce recombinant allergens from Dermatophagoides pteronyssinus under a form appropriate for diagnostic and therapeutic purposes |
682316 |
| 3.4.22.65 | drug development |
the enzyme is a target for design and development of specific inhibitors for treatment of allergic asthma |
732317 |
| 3.4.22.65 | medicine |
affects individuals with allergy, resulting in rhinitis, asthma and/or atopic dermatitits |
665292 |
| 3.4.22.65 | medicine |
allergen is associated with allergic diseases such as bronchial asthma, rhinitis, and atopic dermatitis |
665201, 665290 |
| 3.4.22.65 | medicine |
chimeras assembling Der p 1 and Der p 2 allergens are potential candidate vaccines against house dust mite allergy. But significant solubility and stability issues can limit the application of such chimeras for immunotherapy or diagnostic |
717665 |
| 3.4.22.65 | medicine |
contribution of Der f 1 is particularly relevant in the mattresses and much less so in floor dust from the bedroom or living room, mattress covers (Goratex bedding system) seem to be an obvious option for lowering allergen exposure in sensitized individuals, geographical differences in prevelance of Dermatophagoides farinae in the Netherlands |
668298 |
| 3.4.22.65 | medicine |
cystatin A produced by keratinocytes is the dominant biochemical skin barrier against mite cysteine proteases |
669035 |
